The researchers found that just 13% of participating providers adhered to the recommended low dose (40 mg) of oral prednisone for patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
A recent study is adding insight to previous research indicating that providers are not following consensus guideline on steroid prescribing for patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with a lack of knowledge surrounding the guideline representing a significant barrier.
Although dosing and duration of steroids may vary slightly between guidelines from various organizations, there’s a general consensus that low doses (40 mg) of oral prednisone are recommended; however, despite these guidelines, the researchers of the current study found that among 31 providers, initial dosing ranged from 40 to 625 mg/day, with just 4 (13%) of these providers prescribing 40 mg/day.
The recommendation of 40 mg of oral prednisone stems from the REDUCE trial, which found that higher doses of the steroid did not improve re-exacerbation rates, as well as that time to next exacerbation was longer in the lower-dose group.
The majority (65%) of providers in the current study reported that their dosing choices were based on their clinical experience or prescribing habits while nearly one-third (32%) of providers credited current evidence-based medicine for their dosing decisions. However, notably, just 5 (16%) of providers were able to accurately point to consensus guidelines for AECOPD.
Based on the findings, the researchers argue that “education on consensus guidance will need to be addressed for successful stewardship with a focus on the evidence behind using oral agents, lower doses and differentiating severity of illness.”
The researchers found that years of experience did not significantly sway a provider’s prescribing habits; providers with 4 or less years of experience on average prescribed 215 mg while providers with more than 4 years of experience on average prescribed 312 mg.
However, providers with less experience did prescribe shorter steroid durations, with a median of 5 days compared with a median of 8.5 days among more experienced providers. According to the researchers, this finding could suggest that newly qualified providers may be more up to date on practice guidelines compared with more experienced providers. As a result, education on stewardship will likely also have to incorporate “unlearning” models for these providers.
Looking at the prescribing patterns by their type of practice, the researchers observed that “ED providers reported a starting dose over twice than of non-ED providers. This will, therefore, be a sub-population of particular interest when implementing stewardship activities at the study facility,” they noted.
Reference
Cole J, Smith S. Provider perceptions on steroid dosing in AECOPD: laying the groundwork for steroid stewardship. Clin Respir J. Published online August 6, 2020. doi:10.1111/crj.13247
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Ineligibility, Limitations to PR Uptake in Patients With AECOPD
October 15th 2024Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Read More